AU Patent

AU2011250733C1 — Chemically modified oligonucleotides

Assigned to Alnylam Pharmaceuticals Inc · Expires 2013-09-12 · 13y expired

What this patent protects

This invention relates to compositions and methods for making and using chemically modified oligonucleotides 5 agents for inhibiting gene expression. 2949604_1 (GHMatters) P73650.AU. 1 111ii 1 O==P---O 0 JigandItethering attachment point carie / U,- GAND RM backbone attachment po…

USPTO Abstract

This invention relates to compositions and methods for making and using chemically modified oligonucleotides 5 agents for inhibiting gene expression. 2949604_1 (GHMatters) P73650.AU. 1 111ii 1 O==P---O 0 JigandItethering attachment point carie / U,- GAND RM backbone attachment points carrier - tether O==P--' Ri R w R -R4 FG' R = H, protecting group; A: Rar=r ) + (LIGAND) B:cCrO 0(

Drugs covered by this patent

Patent Metadata

Patent number
AU2011250733C1
Jurisdiction
AU
Classification
—
Expires
2013-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.